According to reports from Business Standard, Camlin Fine Sciences reported a consolidated net loss of ₹31.71 crore in the quarter ended June 2026, representing a significant deterioration from the net loss of ₹9.96 crore recorded during the corresponding quarter of the previous financial year. The company's financial performance showed mixed results with revenue growth offset by operational challenges.
As reported by Business Standard, the company's sales rose 27.51% to ₹519.88 crore in the quarter ended June 2026, compared to ₹407.72 crore during the same period in the previous financial year. This substantial revenue growth indicates strong business momentum despite the company's profitability challenges.
According to the financial data reported by Business Standard, the company's operating profit margin (OPM) declined to 1.79% in the June 2026 quarter from 4.98% in the corresponding quarter of the previous year. Additionally, the company reported a PBDT loss of ₹1.99 crore compared to a PBDT of ₹12.96 crore in the previous year, indicating operational challenges beyond revenue growth.
As reported by Business Standard, the company's profit before tax (PBT) declined by ₹21.15 crore to -₹21.15 crore in the June 2026 quarter from -₹3.18 crore in the previous year. The net loss of ₹31.71 crore represents a significant increase from the net loss of ₹9.96 crore recorded in the corresponding quarter of the previous financial year, indicating substantial operational challenges despite revenue growth.
According to the latest market data, Camlin Fine Sciences is currently trading at ₹125.50 with a 52-week high of ₹128.89 and 52-week low of ₹124.83. The company's market capitalization stands at ₹2,410.69 crore, reflecting its position in the specialty chemicals sector. The stock has shown recent volatility with price movements reflecting market sentiment toward the company's financial performance.
